Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). 2005

Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
Department of Surgery, Kuma Hospital, Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan. ito01@kuma-h.or.jp

BACKGROUND The recent availability of a monoclonal antibody against human telomerase reverse transcriptase (hTERT) has enabled us to investigate the telomerase activity of tissue specimens more easily than by classical TRAP assay. In this study, we studied teromerase activity in thyroid tumors using this antibody. METHODS We immunohistochemically investigated hTERT expression in 166 thyroid neoplasms. RESULTS Normal follicular cells did not express hTERT. In papillary carcinoma, high hTERT expression was observed in 34.5% of cases and it was directly linked to stage and the presence of lymph node metastasis. In follicular carcinoma, 39.2% were classified as the high hTERT expression group, showing a significantly higher incidence than that in follicular adenoma, 9.8%. In anaplastic carcinoma, 73.7% were regarded as the high hTERT expression group, which was larger than the percentages in papillary and follicular carcinomas. We investigated the diagnostic usefulness of hTERT measurement for discriminating follicular carcinoma from adenoma. Its specificity and positive predictive value were high at 90.2% and 83.3%, respectively, while the sensitivity and negative predictive value were low. CONCLUSIONS These results suggest that: i) telomerase activity contributes to anaplastic transformation of differentiated carcinoma and ii) hTERT measurement may contribute to diagnosing follicular carcinoma, but whether it can be applied to preoperative diagnosis by fine-needle aspiration biopsy specimens remains unclear.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D002291 Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed) Carcinomas, Papillary,Papillary Carcinoma,Papillary Carcinomas
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm

Related Publications

Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
January 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
June 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
December 1999, Surgery,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
March 2003, Cancer letters,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
March 2006, Journal of the Egyptian National Cancer Institute,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
August 2017, Journal of cellular physiology,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
September 1998, Cancer research,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
January 2005, Endocrine pathology,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
November 2003, Ai zheng = Aizheng = Chinese journal of cancer,
Yasuhiro Ito, and Hiroshi Yoshida, and Chisato Tomoda, and Takashi Uruno, and Yuuki Takamura, and Akihiro Miya, and Kaoru Kobayashi, and Fumio Matsuzuka, and Kanji Kuma, and Akira Miyauchi
April 1999, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!